Transcendent Capital Group LLC Invests $432,000 in Gilead Sciences, Inc. $GILD

Key Points

• Transcendent Capital Group LLC invested $432,000 in Gilead Sciences by acquiring 3,893 shares in the second quarter.
• Gilead's stock has received several rating upgrades, with Cantor Fitzgerald raising the target price from $129 to $135 and a consensus rating of "Moderate Buy."
• Gilead Sciences declared a quarterly dividend of $0.79, with a yield of 2.7%, and has a dividend payout ratio of 62.95%.

Transcendent Capital Group LLC bought a new stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the second quarter, according to its most recent disclosure with the SEC. The firm bought 3,893 shares of the biopharmaceutical company's stock, valued at approximately $432,000.

A number of other hedge funds have also recently modified their holdings of the stock. Vanguard Group Inc. grew its position in shares of Gilead Sciences by 1.7% in the 1st quarter. Vanguard Group Inc. now owns 117,470,825 shares of the biopharmaceutical company's stock valued at $13,162,606,000 after buying an additional 1,942,433 shares during the last quarter. Price T Rowe Associates Inc. MD grew its position in shares of Gilead Sciences by 314.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company's stock valued at $1,647,484,000 after buying an additional 11,156,382 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of Gilead Sciences by 12.4% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 13,755,481 shares of the biopharmaceutical company's stock valued at $1,541,302,000 after buying an additional 1,520,809 shares during the last quarter. Nuveen LLC purchased a new position in shares of Gilead Sciences in the 1st quarter valued at $620,415,000. Finally, Robeco Institutional Asset Management B.V. grew its position in shares of Gilead Sciences by 12.5% in the 2nd quarter. Robeco Institutional Asset Management B.V. now owns 3,742,656 shares of the biopharmaceutical company's stock valued at $414,948,000 after buying an additional 417,237 shares during the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on GILD shares. Cantor Fitzgerald lifted their target price on shares of Gilead Sciences from $129.00 to $135.00 and gave the company an "overweight" rating in a report on Thursday. Daiwa America raised shares of Gilead Sciences from a "hold" rating to a "strong-buy" rating in a report on Tuesday, August 19th. Rothschild & Co Redburn lifted their target price on shares of Gilead Sciences from $136.00 to $143.00 and gave the company a "buy" rating in a report on Friday, September 12th. Royal Bank Of Canada lifted their target price on shares of Gilead Sciences from $98.00 to $100.00 and gave the company a "sector perform" rating in a report on Wednesday. Finally, Truist Financial raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and lifted their target price for the company from $108.00 to $127.00 in a report on Friday, August 8th. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and six have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $118.08.

Insider Activity

In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of the business's stock in a transaction on Friday, August 15th. The shares were sold at an average price of $118.53, for a total transaction of $3,318,840.00. Following the sale, the insider directly owned 114,168 shares in the company, valued at approximately $13,532,333.04. The trade was a 19.70% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Jeffrey Bluestone sold 5,000 shares of the business's stock in a transaction on Monday, July 14th. The stock was sold at an average price of $109.74, for a total transaction of $548,700.00. Following the sale, the director owned 8,920 shares in the company, valued at $978,880.80. The trade was a 35.92% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 82,000 shares of company stock valued at $9,402,130. Corporate insiders own 0.27% of the company's stock.

Gilead Sciences Stock Performance

NASDAQ:GILD opened at $117.18 on Friday. The firm's fifty day moving average price is $114.65 and its 200 day moving average price is $110.26. Gilead Sciences, Inc. has a 1-year low of $84.17 and a 1-year high of $121.83. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15. The firm has a market cap of $145.40 billion, a price-to-earnings ratio of 23.34, a price-to-earnings-growth ratio of 0.80 and a beta of 0.34.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, beating analysts' consensus estimates of $1.96 by $0.05. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The firm had revenue of $7.08 billion for the quarter, compared to analyst estimates of $6.95 billion. During the same period last year, the firm posted $2.01 EPS. Gilead Sciences's quarterly revenue was up 1.4% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, sell-side analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, September 29th. Investors of record on Monday, September 15th were given a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date was Monday, September 15th. Gilead Sciences's dividend payout ratio (DPR) is 62.95%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.